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Abstract 
Background 
Preoperative, intraoperative and follow-up guidelines for managing occult carcinoma in 
reduction mammoplasty specimens are scant.  
Methods 
We retrospectively analysed the records and pathology reports of 200 patients who had 
undergone reduction mammoplasty at two major public hospitals in Johannesburg, South 
Africa, during 2009 - 2014. Demographic data, their history of breast cancer and preoperative 
screening, and the surgical techniques used and pathological reports were included. In all 
cases, preoperative screening for breast cancer had been negative.  
Results 
All the patients were female, mean age 37.1 years, range 20 - 84 (standard deviation 11.9). 
All reductions were performed using standard techniques. Benign pathology was observed in 
98 patients (49%) and malignant pathology in four (2%). The most common benign 
pathology observed was fibrocystic disease, and the most common malignant pathology 
ductal carcinoma in situ. Patient age correlated significantly with benign or malignant 
disease. 
Conclusions 
Reduction mammoplasty produces tissue that should always be sent for pathological 
assessment. Patients should be stratified by risk, as doing so helps in selecting both the 
surgical setting and the approach to pathological analysis of the specimen. While the 
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incidence of occult carcinoma in reduction mammoplasty specimens is low, all patients 
undergoing the procedure should be informed that tissue will be sent for pathological 
examination, allowing them to prepare to receive possible news of breast cancer and be 
adequately equipped for subsequent decision-making. 
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1 Introduction 
1.1 Background 
Breast reduction (reduction mammoplasty) is a procedure that aims to reduce breast size 
when it has become excessive. It is frequently performed by plastic and breast surgeons to 
relieve macromastia symptoms.[1] It is also performed to obtain breast symmetry after 
contralateral breast cancer operations. [2] In the USA, a 97% increase in the number of 
reduction mammoplasty procedures has been observed.[2] The procedure increases both 
physical and psychological wellbeing and improves quality of life for many patients.[3] 
 
1.2 Occult carcinoma in breast reduction 
Crikelair and Malton[4] published the first reported case of occult carcinoma discovered 
during reduction mammoplasty in 1959. They described the presence of ductal carcinoma 
seen on microscopic examination of surgical specimens. Interestingly, they then published an 
addendum to their initial report when the patient developed another primary tumour in the 
other breast. Since then, as detailed below, many studies have attempted to investigate the 
incidence of occult carcinoma in reduction mammoplasty specimens. 
Snyderman and Lizardo[5] performed a landmark study investigating the presence of occult 
carcinoma in reduction mammoplasty specimens. They examined 5 008 cases and 
demonstrated an incidence of 0.38%. In 1997, Jansen et al.[6] found an incidence of 0.16% in 
their series of 2 576 patients; however, the study design made use of a postal questionnaire 
sent out to consultant plastic surgeons, so it was susceptible to sampling bias. A population-
based series study in Ontario, Canada, found a significantly lower incidence (0.06%) of 
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breast cancer at the time of reduction mammoplasty.[7] While older studies such as this are 
possibly outdated, given the improved awareness of breast malignancy and enhanced clinical 
and radiological techniques used in its detection, in the above series, patients diagnosed with 
breast cancer at the time of reduction mammoplasty were less likely to have advanced cancer 
than the general population and had a better 5-year survival rate. Preoperative screening 
featured both a clinical breast examination and mammography.[7] 
 
1.3 The South African perspective 
In South Africa (SA), the country from which our data are drawn, the latest available 
statistics from the South African National Cancer Registry are from 2006 and show that the 
incidence of breast cancer in SA is 0.029%.[8]  
Macromastia is in itself a factor predisposing to breast cancer.[9] The increased prevalence of 
carcinoma of the breast in these women suggests that they may ultimately develop breast 
cancer following breast reduction. [10] Surgeons should be mindful of this fact, and 
undertake preoperative screening. [11] The recommended triple breast evaluation steps 
outlined in Table 1 must be followed.  
The Royal College of Pathologists, in 2002, in a document aimed to better distribute 
pathology resources, claimed that specimens obtained from reduction mammoplasty 
procedures offered little clinical utility and did not significantly alter patient care. [12] As a 
direct response to this publication, Cook and Fuller, demonstrated that microscopic 
histopathologic examination of breast reduction specimens that appear macroscopically 
normal, had important pathological findings in 2.4% of patients. [13] At present, no South 
African study exists that describes the rational use of pathology services based on the source 
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of specimen. Cook and Fuller’s research, although performed in the United Kingdom, clearly 
demonstrates that microscopic findings could be found even when macroscopy was negative; 
such a conclusion prompts us to believe that histological examination of these specimens 
could still offer some benefit. 
Table 1. Triple breast evaluation 
History Carefully gather a patient history, with the aim of identifying any 
personal or family history of breast cancer, or any predisposing 
factors[9] 
Clinical 
examination 
Undertake a physical examination (including breast and nodal basin 
examination)[2] 
Imaging Undertake imaging, by either a mammogram or breast ultrasound[2,11] 
 
1.4 Intraoperative principles 
At the time of breast reduction, the surgeon has direct exposure to breast tissue and should 
undertake a careful palpation of the breast for any mass lesions. [17] If a malignant lesion is 
encountered at the onset of the procedure, the surgeon should not proceed with the reduction. 
[17] If it is encountered later in the reduction mammoplasty, the procedure should aim for 
adequate oncologic margins. [17] 
 
1.5 Pathological examination of specimens 
Until universal guidelines on risk stratification and pathological examination of reduction 
mammoplasty specimens are developed, all specimens obtained should be submitted for 
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pathological examination. [16] Histology should be of the same standard for all breast 
reduction specimens and should not differ with regards to age or other breast cancer risk 
factors. [17] 
 
1.6 Treatment of breast cancer discovered during breast reduction 
Diagnosis of breast cancer prior to reduction mammoplasty is vital as management and 
treatment options may change significantly.[14] A woman would be unlikely to opt to 
proceed with reduction mammoplasty without having both a biopsy and a multidisciplinary 
team decision on the management of malignancy. The diagnosis of breast cancer during 
reduction mammoplasty reduces the number of appropriate surgical options available and 
also complicates further treatment of the cancer.[2] 
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2 Methods 
The worldwide incidence of occult carcinoma in reduction mammoplasty specimens is low. 
No study examining these pathological findings has been performed in SA. As discussed, 
studies have been conducted in developed countries, but this information may not be 
accurately extrapolated to developing countries such as SA. 
 
2.1 Study Aim 
The aim of this local study is to describe the spectrum of pathological findings in reduction 
mammaplasty specimens, both benign and malignant, in the South African setting.  
 
2.2 Study Objectives 
• To measure the incidence of abnormal pathologic findings, both benign and 
malignant, in reduction mammaplasty specimens in two high volume, multi-
disciplinary surgical centres in Johannesburg, South Africa 
• To stratify the incidence of pathologic findings in reduction mammaplasty specimens 
in different age groups 
• To identify specific pathologic lesions in reduction mammaplasty specimens and 
stratify these according to age 
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2.3 Study area  
Chris Hani Baragwanath Academic Hospital (CHBAH) is a public hospital situated in 
Soweto, Johannesburg, South Africa. It serves a mostly black African, lower-income 
population of 2.5 million. Mammoplasty procedures are performed at CHBAH free of charge 
to the patient. Helen Joseph Hospital (HJH) is a public hospital situated in Westdene, 
Johannesburg, and serves a population of approximately 198 000 of mixed socioeconomic 
status. Mammoplasty procedures are not provided free of charge at HJH, but the cost is lower 
than that at a private hospital. 
 
2.4 Study design 
A retrospective record review was performed of all patients who had undergone reduction 
mammoplasty procedures at CHBAH or HJH between January 2009 and January 2014, 
inclusive. Along with demographic data, patient histories of breast cancer, findings on 
preoperative screening, surgical techniques and pathological reports were recorded. 
 
2.5 Inclusion criteria 
To be included in the study sample, each patient had to meet the following three inclusion 
criteria: no preoperative history or examination suggestive of any breast disease; reduction 
mammoplasty performed on one or both breasts, using standard surgical techniques; and 
surgical specimens submitted for pathological review. 
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2.6 Preoperative screening 
A detailed history was obtained, and aimed to identify previous or current breast disease and 
personal or family risk factors for breast disease. Screening further included clinical 
examination of the breasts as well as imaging – specifically, breast ultrasound for patients 
<35 years of age, and mammography for those aged ≥35 years or older. Preoperative imaging 
not only enabled significant breast disorders to be identified before surgery, but provided a 
control for detection of abnormalities after surgery had been performed.[15] Our institutional 
protocol dictates that preoperative screening of all reduction mammaplasty patients should be 
performed routinely however it is unknown whether this is the case with other Plastic 
Surgeons in South Africa. This uncertainty is not unique to South Africa, as the rate of 
preoperative screening before this procedure is also unknown in developed countries, such as 
the United Kingdom. [16] 
 
2.7 Pathological assessment 
Pathological findings were categorised into two broad groups: benign lesions and malignant 
lesions. Fibrocystic disease was included under benign pathology. Malignant pathology 
included carcinoma in situ. Only cases with at least two random blocks per breast were 
included. All specimens had been submitted to the SA National Health Laboratory Service. 
 
2.8 Data Collection 
Patients undergoing reduction mammaplasty procedures during this time period will be 
identified from theatre booking lists. The medical notes and histopathology reports for 
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surgical specimens from these procedures will be obtained. Information recorded will be 
patient demographics (age and race), diagnosis, laterality of procedure (unilateral or 
bilateral), specimen weight, and pathological findings. It will also be determined whether the 
patients received any pre-operative investigation, in the form of clinical breast examination, 
mammography or breast ultrasound. This information will be recorded on a data collection 
sheet (see Appendix D).  
 
2.9 Statistical analysis 
The Statistical Package for the Social Sciences (SPSS) 20.0 (SPSS Inc., USA) software 
program for Macintosh was used in data analysis. Descriptive results were expressed as 
means and standard deviations (SDs). Statistical evaluations were performed using the non-
parametric Mann-Whitney U-test. The level of significance was set at p<0.05. 
 
2.10 Ethics approval 
Ethical approval was obtained from the Human Research Ethics Committee of the University 
of the Witwatersrand (clearance No. M140239). All study participants were given a study 
number to ensure anonymity of data.  
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3 Results 
 
Figure 1. Patient Inclusion in Study 
 
 
A total of 209 patients were identified for inclusion in the study. Nine were excluded because 
their operative specimens had not been submitted for pathological analysis. The 200 patients 
included were all female, with a mean (SD) age of 37.1 (11.9) years. The youngest patient 
was 20 years of age, and the oldest 84. 
All patients had undergone a preoperative work-up including history-taking, clinical 
examination and imaging. 
All reductions were performed using standard techniques, with 195 procedures being bilateral 
and five unilateral. The mean (SD) weight of specimens submitted for pathological review 
was 1 002.8 (652.1) g. 
Benign pathology was observed in 98/200 patients (49%) and malignant pathology in four 
(2%). Specific pathological findings are listed in Table 2. Positive histological findings in 
individual patients, coupled with their ages, are tabulated in Table 3. Benign pathology was 
observed at a mean age of 46.5 years and malignant pathology at a mean of 50.2 years.  
Assessed for eligibility (n=209) 
Excluded (n=9) 
• Specimens had not been submitted for 
pathological analysis 
Included in study (n=200) 
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Table 2. Specific benign and malignant lesions 
Pathological diagnosis n  
Benign lesions (N=98) 
Atypical ductal hyperplasia 1 
Phyllodes 1 
Ductal ectasia 2 
Lipoid necrosis 2 
Ductal hyperplasia 8 
Fibroadenoma 14 
Sclerosing adenosis 20 
Fibrocystic change 50 
Malignant lesions (N=4) 
Ductal carcinoma in situ 3 
Invasive lobular carcinoma 1 
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Table 3. Individual Patient Age and Histological 
Findings 
 
Age Pathological diagnosis No.  of patients in Category 
35 FIBROCYSTIC CHANGE 7 
36 FIBROCYSTIC CHANGE 5 
37 FIBROCYSTIC CHANGE 3 
38 FIBROCYSTIC CHANGE 5 
39 FIBROCYSTIC CHANGE 5 
40 FIBROCYSTIC CHANGE 2 
41 FIBROCYSTIC CHANGE 5 
42 FIBROCYSTIC CHANGE 5 
43 FIBROCYSTIC CHANGE 5 
44 FIBROCYSTIC CHANGE 5 
45 FIBROCYSTIC CHANGE 2 
45 LIPOID NECROSIS 2 
46 SCLEROSING ADENOSIS 5 
47 SCLEROSING ADENOSIS 6 
48 SCLEROSING ADENOSIS 4 
49 SCLEROSING ADENOSIS 5 
50 
ATYPICAL DUCTAL 
HYPERPLASIA 
1 
50 DCIS 3 
51 DUCTAL ECTASIA 2 
51 DUCTAL HYPERPLASIA 1 
51 
LOBULAR NEOPLASIA, 
FIBROCYSTIC CHANGE 
1 
51 PHYLLODES 1 
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52 DUCTAL HYPERPLASIA 2 
54 DUCTAL HYPERPLASIA 2 
55 DUCTAL HYPERPLASIA 2 
56 DUCTAL HYPERPLASIA 1 
56 FIBROADENOMA 1 
57 FIBROADENOMA 4 
59 FIBROADENOMA 1 
60 FIBROADENOMA 2 
62 FIBROADENOMA 3 
65 FIBROADENOMA 2 
69 FIBROADENOMA 1 
84 FIBROCYSTIC CHANGE 1 
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Figure 2. Benign Lesions by Type 
 
 
The Shapiro-Wilk test of normality revealed that the age and average specimen weight 
variables were not normally distributed. A Mann-Whitney U-test showed that age was a 
variable significantly associated with the presence both of benign disease (p<0.0001) and 
malignant disease (p=0.012). No significant difference was found when the presence of 
benign or malignant disease was correlated with specimen weight. Furthermore, there was no 
significant difference when specific malignant lesions were compared, probably owing to the 
small sample number. 
 
  
Atypical ductal 
hyperplasia, 1 
Phyllodes, 1 Ductal ectasia, 2 
Lipoid necrosis, 2 
Ductal hyperplasia, 8 
Fibroadenoma, 14 
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Fibrocystic change, 
50 
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Figure 3. Statistical Analysis of Age vs the Presence of Malignant Disease 
 
 
 
Figure 4. Statistical Analysis of Age vs the Presence of Benign Disease 
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4 Discussion 
Reduction mammoplasty produces a variable amount of tissue that should always be sent for 
pathological examination.[17] The procedure is of both cosmetic and oncological 
significance.[18] Its oncological significance is based primarily on the observation that breast 
cancer risk is reduced proportionate to the amount of breast tissue removed during the 
procedure.[19] Additionally, breast cancer encountered before, during, or after reduction 
mammoplasty requires a multidisciplinary approach to treatment, like any other breast 
cancer. 
Malignant pathology was observed in 2% (n=4) of the 200 patients in this study. The 
incidence of occult breast carcinoma in other series ranges from 0.06% to 4.6%, with the 
most recent study in 2013 reporting a 0.56% rate of malignant pathology (including both 
invasive carcinoma and carcinoma in situ).[20] Differences in incidence arise because some 
studies include patients with previous or current breast disease, while in others, carcinoma in 
situ was not included. In addition, the pick-up of abnormal pathology increases in proportion 
to the degree of the pathological analysis.[21] In 1984, Nielsen et al.[22] showed through 
intense pathological scrutiny of breast specimens obtained from autopsy (200 or more blocks 
per specimen) that 14 - 16% of these specimens had occult carcinoma or carcinoma in situ. A 
future direction for our study would be a prospective investigation including a higher number 
of blocks per specimen to increase the rate of pick-up of pathological lesions. 
Freedman et al.[23] found that the incidence of both premalignant and malignant lesions 
increased with increasing patient age; this trend was also seen in the current study, the 
significance extending to benign lesions as well as premalignant and malignant lesions. The 
malignant conditions encountered were largely (75%) of the ductal carcinoma in situ variety. 
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The most common benign lesion encountered was fibrocystic change, followed by sclerosing 
adenosis. We found fibroadenoma, classically a condition encountered in younger 
individuals, to be more common among older patients. Fibroadenomas in older patients tend 
to exhibit atrophy coupled with calcifications, however these are still considered benign 
conditions.[24] The weight of the specimen was not found to influence the presence of 
benign or malignant disease. 
In this study, benign breast disease was observed in 98/200 patients (49%). In patients not 
undergoing reduction mammoplasty, benign breast disease is, in the majority of cases, a 
pathology that is identified when breast imaging abnormalities are found and/or a lump is 
found on clinical examination. Not all benign breast disease is equal, with different 
histological categories conferring different risks for breast cancer. Proliferative lesions 
without atypia confer a 1.5 to 2-fold increase in risk for breast cancer, while the risk may be 
as high as 4 to 5-fold in proliferative lesions with atypia. [25] The detection of benign breast 
disease in specimens submitted from reduction mammoplasty procedures does not ultimately 
alter the ongoing care of these patients and it could be argued that histologically examining 
these specimens is a waste of scarce resources in a country such as South Africa. The 
challenge arises in patients with a negative preoperative screening and the finding of breast 
disease intraoperatively; being selective in which specimens should be submitted for 
histology based on a presumed benign diagnosis, would require the surgeon to make this 
diagnosis intraoperatively based solely on his or her clinical expertise. In my opinion, even a 
single missed diagnosis of malignant breast disease due to the surgeon incorrectly classifying 
this disease as benign, intraoperatively, is inexcusable and the suggestion remains that no 
assumptions be made on whether a pathology detected intraoperatively is benign or 
malignant. 
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Patients who undergo reduction mammoplasty at CHBAH or HJH are followed up at 6 and 
12 months. They are given advice regarding further screening, and are also followed up as 
part of SA’s standard breast cancer screening programmes. Long-term follow-up of these 
patients would be of value to ascertain the incidence of breast cancer in the remaining breast 
tissue. Furthermore, in countries with a high prevalence of HIV/AIDS, variables such as HIV 
positivity and CD4 count would be useful data to capture and examine in future research. 
These data were not available for our retrospective review, but could be included in future 
prospective studies. 
Every patient in the current study had had preoperative screening, despite the scant 
availability of universal guidelines for preoperative assessment and pathological assessment. 
All methods of breast reduction allow for good exposure of breast parenchyma, and for direct 
visualisation and palpation of other segments; theoretically, any palpable tumour therefore 
can and should be detected at that time.[1] Titley et al.[26] suggested in 1996 that surgical 
specimens be separated clearly into left and right, and a marker stitch be placed in the main 
specimen, possibly separating tissues into quadrants. Since the majority of reduction 
mammoplasty specimens do not have occult carcinoma, it would be difficult to convince all 
surgeons to ink the margins of surgical specimens; however, it is reasonable to insist that 
specimens from women at an increased risk of developing breast cancer be inked for 
orientation.[2] 
More recently it has been suggested that patients undergoing reduction mammoplasty be 
stratified according to risk; doing so would dictate the setting in which surgery should take 
place and the approach to pathological analysis of the specimen.[18] Table 4 outlines the 
approach to risk stratification and in what settings surgery should take place. 
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Table 4. Risk stratification for reduction mammoplasty patients[16] 
Risk group Features 
Setting in which 
surgery should take 
place Approach to specimen 
High risk Personal history of 
breast cancer 
BRCA1 or BRCA2 
mutations 
Previous radiation to 
the chest 
Personal history of 
cancer syndromes 
Pathology and 
surgical oncology 
services should be 
available 
Margins should be inked 
and specimens orientated 
and divided into individual 
containers per segment 
resected 
Intermediate 
risk 
Family history of 
breast cancer 
Proliferative benign 
breast lesions 
Pathology and 
surgical oncology 
services should be 
available 
Inking of margins may be 
omitted  
Low risk Age <30 years 
No family history of 
breast cancer 
Surgery may be 
performed at an 
outpatient centre 
Specimen may be sent in 
two containers: left and 
right breast 
 
No universal guidelines exist in South Africa for the handling of these specific specimens, 
although some institutional protocols dictate that all specimens be submitted, while other 
institutions suggest that only high risk specimens be submitted. In a resource-poor setting, 
utilitarianism should be the ideal, and in the case of pathological examination of reduction 
mammoplasty specimens, stratifying patients by risk could direct the Plastic Surgeon in 
selecting which specimens are submitted for review, and furthermore direct the Pathologist 
on the most cost-effective examination of these specimens. Until risk stratification and 
specimen selection for histopathology is standardised, all specimens should be submitted for 
pathological examination. Although it is simpler that all specimens be handled or marked 
intraoperatively in the same manner, the suggestion that different approaches to the specimen 
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based on risk stratification means that in low risk individuals, time is not wasted marking 
these specimens. Higher risk demands more time be allocated to ensuring proper marking and 
orientation of these specimens. 
Pathological examination of reduction mammoplasty specimens is different in each 
institution. Dotto et al suggest that in routine reduction mammoplasty specimens, a 
macroscopic inspection followed by microscopic examination of 4 sections of tissue per 
specimen is sufficient. [9] Our study demonstrated a mean weight of 1002,8g per specimen, 
thus it is conceivable that only 4 sections of tissue (2 slides) would indeed not be sufficient, 
however the detection rate was still relatively high (49% benign, 2% malignant). Again no 
South African guidelines exist on the minimum number of sections that should examined in 
these specimens. 
Patients diagnosed with breast cancer at the time of reduction mammoplasty are likely to be 
treated with a completion mastectomy.[7] It is unknown at present whether this is the actual 
management employed by South African plastic surgeons, and whether South African 
patients are being informed of the eventuality of a mastectomy if cancer is detected 
intraoperatively. The basis of the decision to proceed to completion mastectomy is the 
rearrangement of tissues during the procedure, as well as the possibility of tumour seeding in 
the normal breast. Discovery of a breast carcinoma during or after a reduction mammoplasty 
poses a number of technical challenges: a large field of dissection, including a breach of 
pectoral fascia in certain areas; a larger skin incision; and possible contamination of the other 
breast during bilateral procedures.[14] The suggested technique, if breast cancer is discovered 
in pathological examination of surgical specimens from reduction mammoplasty, is a 
completion mastectomy that includes pre-existing incisions from the reduction mammoplasty 
procedure.[27] Reduction mammoplasty should not be considered a contraindication to 
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sentinel lymph node biopsy, as many lymphatic channels remain intact and most breast 
reduction techniques involve incisions on the inferior aspect of the breast.[28] 
Many philosophical debates on ethics and informed consent have arisen in recent years. In 
the UK, screening for breast cancer is not recommended for any woman under the age of 
50.[29] Furthermore, the US Preventive Services Task Force’s breast screening 
recommendations recently indicated that mammography is of no benefit for patients under 
the age of 50.[30] Given these recommendations, many young women worldwide who are 
undergoing reduction mammoplasty are in effect undergoing a ‘screening procedure’ without 
their informed consent.[31] Although the incidence of occult carcinoma among reduction 
mammoplasty specimens is low, all patients undergoing the procedure should be fully 
informed that the tissue will be sent for pathological examination, as doing so allows them to 
prepare for the possibility of receiving news of breast cancer, and to be adequately equipped 
for the decision-making that will follow.[31] Indeed, ‘The primary intent of mammoplasty is 
cosmetic, but it is a medical procedure, taking place in a medical setting, and those 
performing it have a fiduciary obligation towards their patients’ health and wellbeing.’[31] 
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Conclusion 
It has been demonstrated that, even in developing countries, it is of vital importance that 
surgeons aim to adequately investigate reduction mammoplasty candidates preoperatively 
and ensure that all tissue is submitted for pathological analysis. During the informed consent 
process for the procedure, patients should be fully informed of the potential consequences of 
the pathological analysis of surgical specimens obtained. Multidisciplinary approaches to 
breast cancer treatment should always be included for patients undergoing reduction 
mammoplasty who are diagnosed with breast cancer. Age was found to correlate significantly 
with the presence of benign or malignant disease in reduction mammoplasty specimens. 
Further areas of study exist, and the results thereof could increase our understanding of the 
various pathological lesions found in reduction mammoplasty specimens. 
A need for developing clear guidelines for preoperative investigation, intraoperative marking 
and pathological examination of reduction mammoplasty specimens is evident, and should be 
directed by the requirement of cost-effectiveness in a resource-limited setting such as South 
Africa. These guidelines could further steer South African Plastic Surgeons towards a unified 
approach to these patients as much uncertainty exists on how these patients are currently 
handled. We hope that this study serves as a starting point for developing guidelines that will 
not only be of utility in South Africa but for Plastic Surgeons performing reduction 
mammoplasty in any setting. 
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